ME02451B - Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink - Google Patents

Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink

Info

Publication number
ME02451B
ME02451B MEP-2016-116A MEP2016116A ME02451B ME 02451 B ME02451 B ME 02451B ME P2016116 A MEP2016116 A ME P2016116A ME 02451 B ME02451 B ME 02451B
Authority
ME
Montenegro
Prior art keywords
phosphoinositide
kinase inhibitor
binding moiety
zinc binding
zinc
Prior art date
Application number
MEP-2016-116A
Other languages
German (de)
English (en)
French (fr)
Inventor
Xiong Cai
Haixiao Zhai
Chengjung Lai
Changgeng Qian
Rudi Bao
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of ME02451B publication Critical patent/ME02451B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2016-116A 2011-04-01 2012-03-30 Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink ME02451B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US201161559489P 2011-11-14 2011-11-14
EP12764605.7A EP2694075B1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
PCT/US2012/031361 WO2012135571A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Publications (1)

Publication Number Publication Date
ME02451B true ME02451B (me) 2016-09-20

Family

ID=46931927

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2019-179A ME03523B (me) 2011-04-01 2012-03-30 Inhibitori fosfoinozitid 3 kinaze sa dijelom koji vezuje cink
MEP-2016-116A ME02451B (me) 2011-04-01 2012-03-30 Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2019-179A ME03523B (me) 2011-04-01 2012-03-30 Inhibitori fosfoinozitid 3 kinaze sa dijelom koji vezuje cink

Country Status (30)

Country Link
US (7) US8710219B2 (me)
EP (2) EP3111938B1 (me)
JP (3) JP6242331B2 (me)
KR (2) KR101902325B1 (me)
CN (2) CN103582483B (me)
AU (1) AU2012236367B2 (me)
BR (1) BR112013025340B1 (me)
CA (1) CA2830822C (me)
CL (1) CL2013002823A1 (me)
CY (2) CY1117785T1 (me)
DK (2) DK3111938T3 (me)
EA (1) EA022434B9 (me)
ES (2) ES2577982T3 (me)
HK (1) HK1194969A1 (me)
HR (2) HRP20160545T1 (me)
HU (2) HUE045041T2 (me)
IL (2) IL228588A (me)
LT (1) LT3111938T (me)
ME (2) ME03523B (me)
MX (1) MX340577B (me)
PE (1) PE20141382A1 (me)
PL (2) PL3111938T3 (me)
PT (2) PT2694075T (me)
RS (2) RS59219B1 (me)
SG (2) SG193563A1 (me)
SI (2) SI3111938T1 (me)
SM (1) SMT201600179B (me)
TW (1) TWI571469B (me)
WO (1) WO2012135571A1 (me)
ZA (2) ZA201307082B (me)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG196815A1 (en) 2009-01-08 2014-02-13 Curis Inc Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
AU2012236367B2 (en) 2011-04-01 2014-10-09 Curis, Inc. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
UA114900C2 (uk) 2011-11-14 2017-08-28 Ігніта, Інк. Похідні урацилу як інгібітори axl і c-met-кінази
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
AU2016250972B2 (en) * 2015-04-21 2019-01-17 Chengdu Zenitar Biomedical Technology Co., Ltd. Purinyl-n-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
CN109476710B (zh) * 2016-07-19 2021-11-23 国立植物基因组研究所 抗真菌病原体的新蛋白质
MA46728A (fr) * 2016-11-02 2019-09-11 Curis Inc Polythérapie avec un inhibiteur de phosphoinositide 3-kinase avec une fraction de liaison au zinc
SG11202102343QA (en) 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CA2407593C (en) 2000-04-27 2011-01-11 Yamanouchi Pharmaceutical Co. Ltd. Fused heteroaryl derivatives
DE60321548D1 (de) 2002-03-13 2008-07-24 Janssen Pharmaceutica Nv Carbonylamino- derivativate als neue inhibitoren von histone deacetylase
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
AU2003218738B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
EP1485099B1 (en) 2002-03-13 2010-07-07 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
WO2004067535A1 (ja) 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited チエノピリミジン化合物およびその用途
AU2005230682B2 (en) * 2004-04-05 2010-10-21 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
JP4862654B2 (ja) 2004-10-08 2012-01-25 アステラス製薬株式会社 芳香環縮合ピリミジン誘導体
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP1855760A2 (en) 2005-02-03 2007-11-21 TopoTarget UK Limited Combination therapies using hdac inhibitors
WO2006122926A1 (en) 2005-05-18 2006-11-23 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
US7834011B2 (en) 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
WO2007082880A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
MX2008013583A (es) 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
TWI409268B (zh) 2006-04-26 2013-09-21 Hoffmann La Roche 醫藥化合物
EP2402347A1 (en) 2006-04-26 2012-01-04 F. Hoffmann-La Roche AG Pharmaceutical compounds
EP2018366A4 (en) 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES HAVING MIXED PROPERTIES OF VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITOR
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
AU2007296740B2 (en) 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
JP5580592B2 (ja) 2006-09-11 2014-08-27 キュリス,インコーポレイテッド 亜鉛結合部分を含むキナゾリン系egfrインヒビター
WO2008033747A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
KR101433629B1 (ko) 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 티로신 키나아제 억제제
US8399452B2 (en) 2006-10-28 2013-03-19 Methylgene Inc. Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
US9487533B2 (en) * 2006-12-07 2016-11-08 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
EP2114949A1 (en) 2006-12-07 2009-11-11 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
PE20090519A1 (es) 2007-02-15 2009-05-29 Novartis Ag Composicion farmaceutica que contiene n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]-metil]-fenil]-2e-2-propenamida
JP2010522163A (ja) 2007-03-20 2010-07-01 キュリス,インコーポレイテッド 亜鉛結合部位を含むRafキナーゼインヒビター
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
PE20090678A1 (es) * 2007-09-12 2009-06-27 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
WO2009058895A1 (en) 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
JP2011525535A (ja) 2008-06-24 2011-09-22 武田薬品工業株式会社 PI3K/mTOR阻害剤
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
SG196815A1 (en) * 2009-01-08 2014-02-13 Curis Inc Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010105008A2 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
AU2010314287A1 (en) 2009-10-12 2012-05-03 F. Hoffmann-La Roche Ag Combinations of a PI3K inhibitor and a MEK inhibitor
WO2011130628A1 (en) 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
AU2012236367B2 (en) * 2011-04-01 2014-10-09 Curis, Inc. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
ES2708669T3 (es) 2011-08-01 2019-04-10 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de MEK
ES2953441T3 (es) 2015-06-25 2023-11-13 Immunomedics Inc Combinación de anticuerpos anti-hla-dr o anti-Trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer
MA46728A (fr) * 2016-11-02 2019-09-11 Curis Inc Polythérapie avec un inhibiteur de phosphoinositide 3-kinase avec une fraction de liaison au zinc

Also Published As

Publication number Publication date
DK2694075T3 (en) 2016-08-01
AU2012236367B2 (en) 2014-10-09
MX2013011132A (es) 2014-03-12
PT2694075T (pt) 2016-07-11
CA2830822C (en) 2018-10-02
US10111864B2 (en) 2018-10-30
HK1194969A1 (zh) 2014-10-31
EA201301114A1 (ru) 2014-04-30
KR20140023333A (ko) 2014-02-26
ES2577982T3 (es) 2016-07-19
JP6275784B2 (ja) 2018-02-07
US20220168284A1 (en) 2022-06-02
DK3111938T3 (da) 2019-07-01
HRP20160545T1 (hr) 2016-06-17
IL228588A (en) 2016-11-30
US20140243330A1 (en) 2014-08-28
ZA201406167B (en) 2015-03-25
BR112013025340B1 (pt) 2021-12-21
ME03523B (me) 2020-04-20
US8710219B2 (en) 2014-04-29
LT3111938T (lt) 2019-06-25
IL248597B (en) 2018-04-30
US20130090335A1 (en) 2013-04-11
RS59219B1 (sr) 2019-10-31
MX340577B (es) 2016-07-13
SG193563A1 (en) 2013-11-29
EA022434B9 (ru) 2016-02-29
US20190091211A1 (en) 2019-03-28
JP6242331B2 (ja) 2017-12-06
HRP20191091T1 (hr) 2019-09-20
US20200215039A1 (en) 2020-07-09
CA2830822A1 (en) 2012-10-04
EP2694075A4 (en) 2014-10-01
CY1117785T1 (el) 2017-05-17
IL248597A0 (en) 2016-12-29
TWI571469B (zh) 2017-02-21
NZ615586A (en) 2015-02-27
EP2694075B1 (en) 2016-04-27
EP3111938B1 (en) 2019-05-08
US20160185796A1 (en) 2016-06-30
JP2016188255A (ja) 2016-11-04
TW201247678A (en) 2012-12-01
US10543197B2 (en) 2020-01-28
ZA201307082B (en) 2015-04-29
CN103582483B (zh) 2016-02-17
AU2012236367A1 (en) 2013-04-18
JP2018052987A (ja) 2018-04-05
WO2012135571A1 (en) 2012-10-04
RS54903B1 (sr) 2016-10-31
US20170304279A1 (en) 2017-10-26
KR20180108848A (ko) 2018-10-04
US9657032B2 (en) 2017-05-23
SG10201602569RA (en) 2016-05-30
IL228588A0 (en) 2013-12-31
NZ705039A (en) 2016-03-31
PL3111938T3 (pl) 2019-09-30
JP2014509653A (ja) 2014-04-21
PL2694075T3 (pl) 2016-09-30
US11654136B2 (en) 2023-05-23
HUE028910T2 (en) 2017-01-30
HUE045041T2 (hu) 2019-12-30
PT3111938T (pt) 2019-07-10
ES2733128T3 (es) 2019-11-27
SI2694075T1 (sl) 2016-07-29
EP2694075A1 (en) 2014-02-12
KR101902325B1 (ko) 2018-09-28
US9249156B2 (en) 2016-02-02
CL2013002823A1 (es) 2014-04-11
CN105461736B (zh) 2018-06-12
PE20141382A1 (es) 2014-11-04
EP3111938A1 (en) 2017-01-04
CN105461736A (zh) 2016-04-06
SI3111938T1 (sl) 2019-08-30
EA022434B1 (ru) 2015-12-30
SMT201600179B (it) 2016-08-31
BR112013025340A2 (pt) 2016-12-13
CN103582483A (zh) 2014-02-12
CY1121825T1 (el) 2020-07-31
US11135205B2 (en) 2021-10-05

Similar Documents

Publication Publication Date Title
IL237727A0 (en) Inhibitors of phosphoinositide 3-kinase with a zinc-binding group
IL248597A0 (en) A phosphoinositide-3-kinase inhibitor with a zinc binding site
HK1258842A1 (zh) 用於檢測活組織上的生物膜的組合物
GB2481513B (en) A magazine add-on
ZA201306639B (en) Attachment mechanism for a contaienr
EP2611352A4 (en) DISHWASHER
EP2696949A4 (en) BINDING
GB2484514B (en) A mechanism
GB201200412D0 (en) A rake
AU332267S (en) A bumper guard
AU332323S (en) A bumper guard
GB201013994D0 (en) A camrea accessory
GB201116046D0 (en) A cover
GB201010041D0 (en) Drawer assembly for a vehicle
GB201116008D0 (en) A kennel